Cellsafe Malaysia

About

As of 3 Oct 2024, CytoMed Therapeutics of Singapore has acquired Cellsafe Group through its subsidiary IPSC Depository Sdn Bhd, which in turn is a subsidiary of LongevityBank Pte Ltd.

Cellsafe Biotech Group previously operated family cord blood banks in both Malaysia and Indonesia. Cellsafe was the first cord blood bank in Malaysia to be accredited by AABB in early 2015. Cellsafe was also the first cord blood bank in Malaysia to purchase automated stem cell processing equipment.

In late 2024 CytoMed Therapeutics acquired both the cord blood banking license and the assets from Cellsafe International Sdn Bhd (in Liquidation) for a cash purchase of RM 2.3 million (US$ 490,000). Since then, the websites of Cellsafe Group have been down. The cord blood inventory of Cellsafe was 12,000. At the end of 2024, CytoMed Therapeutics reported income of US$ 624,771, up 6% from 2023 despite the investment in acquiring Cellsafe.

CytoMed Therapeutics is dedicated to the development of donor-derived (allogeneic), cell-based, off-the-shelf immunotherapies. The acquisition of the Cellsafe cord blood license will help CytoMed to develop Gamma Delta (γδ) T-cell therapies to treat cancers. Their technology platform sources the T-cells from donated cord blood.